Undifferentiated Carcinoma

histology

Identifier: CI-CAN-00001624
Entity page: /cancer/undifferentiated-carcinoma ↗
Edges: 238

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Undifferentiated Carcinoma approved for …APPROVED_FORderived4 of 4
← approved for	Dabrafenibsmall molecule FDA (US) · approved · 2023-03-16 · the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an F…	—	approved	Thyroid Gland Anaplastic Carcinoma	1	Regulatory	openfda	graph →
← approved for	Trametinib

Undifferentiated Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 72show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 42 trials (11 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	42	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 34 trials (10 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 20 trials (5 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 19 trials (4 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 11 trials (5 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall molecule 10 trials (4 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 9 trials (4 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Trametinibsmall molecule 8 trials (5 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Erlotinib Hydrochloridesmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Cetuximabmonoclonal antibody 5 trials (0 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Dabrafenibsmall molecule 5 trials (4 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenvatinibsmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 5 trials (5 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Pemetrexedsmall molecule 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Undifferentiated Carcinoma	5	Observed	clinicaltrials	graph →

Undifferentiated Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 72show all (up to 200)

→ investigated in trials for

Paclitaxelsmall molecule

42 trials (11 active) · roll-up of the cancer and its descendants

—

Undifferentiated Carcinoma

Observed

Undifferentiated Carcinoma studied in …STUDIED_INderived10 of 162show all (up to 200)
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 162 trials mapped (50 active)	—	—	Fallopian Tube Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 162 trials mapped (50 active)	—	—	Fallopian Tube Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 162 trials mapped (50 active)	—	—	Endometrial Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 162 trials mapped (50 active)	—	—	Endometrial Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06814496Phase 1/Phase 2 · recruiting Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors · condition mapped ONTOLOGY_EXACT · 162 trials mapped (50 active)	—	—	Sinonasal Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06176989Phase 2 · recruiting Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors · condition mapped CURATED_BROADER · 162 trials mapped (50 active)	—	—	Sinonasal Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06235216Phase 2 · recruiting Sacituzumab govitEcan in THYroid Cancers · condition mapped ALIAS · 162 trials mapped (50 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04723095recruiting Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix · condition mapped ONTOLOGY_EXACT · 162 trials mapped (50 active)	—	—	Cervical Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07181720Phase 1 · suspended CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors · condition mapped ALIAS · 162 trials mapped (50 active)	—	—	Thyroid Gland Anaplastic Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 162 trials mapped (50 active)	—	—	Ovarian Undifferentiated Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains